60 Degrees Pharmaceuticals has entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, expecting gross proceeds of approximately $1.0 million before fees. The offering consists of 574,713 shares of common stock or pre-funded warrants, plus series A and short-term series B warrants each to purchase up to 574,713 shares, at a combined price of $1.74 per share. Both warrant series carry an exercise price of $1.49 per share and are exercisable immediately, with series A warrants expiring five years and series B warrants expiring twenty-four months from the effective date of the resale registration statement. H.C. Wainwright & Co. is acting as exclusive placement agent, and the closing is expected on or about July 31, 2026. The company plans to use the net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals, Inc. Common StockCompany prices a dilutive private placement at-the-market, raising $1M but issuing shares and warrants that dilute existing holders.